MAPT and Alzheimer disease: There were two clinical trials on AD aiming to concurrently collect heart rate variability along with EEG metrics and neuropsychiatric measures (NCT05723172) or PET amyloid burden and PET tau deposition, along with EEG metrics (NCT03880240).